<--GAT-->
Clinical Topics

New Therapy Options Recently Approved for Hodgkin’s Lymphoma

by U.S. Medicine

June 12, 2018
Reed-Sternberg cell; photograph shows normal lymphocytes compared with a Reed-Sternberg cell, which are large, abnormal lymphocytes that may contain more than one nucleus. These cells are found in Hodgkin lymphoma.

WASHINGTON — While the availability of novel therapies is making the future brighter for non-Hodgkin’s lymphoma (NHL) patients, new treatments also are coming on line for Hodgkin’s lymphoma, which is a hematological cancer distinct from NHL.

While both Hodgkin’s and non-Hodgkin’s lymphoma are lymphocyte malignancies, Hodgkin lymphoma is distinguished by the presence of Reed-Sternberg cells, which are mature B cells that have become malignant, are unusually large, and carry more than one nucleus. The symptom leading to diagnosis usually is enlarged lymph nodes.

Both cancers are recognized by the VA as presumptive diseases associated with exposure to Agent Orange or other herbicides during military service. Because of that exposure, veterans and their survivors might be eligible for VA benefits related to those diseases. Hodgkin’s, however, has a much lower rate among veterans, 0.25% of all cancers diagnosed at the VA, compared to NHL at 3.34%, according to a report last year in Military Medicine.1

Based on approval in March by the Food and Drug Administration, brentuximab vedotin also now can be used to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy.

“Today’s approval represents an improvement in the initial treatment regimens of advanced Hodgkin lymphoma that were introduced into clinical practice more than 40 years ago,” said Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “This approval demonstrates our commitment to approving advancements in treatment that give prescribers and patients different options for care.”

The drug, marketed as Adcetris, combines an antibody and drug, allowing the antibody to direct the drug to a target on CD30 lymphoma cells. Adcetris has also been previously approved by the FDA to treat cHL after relapse or cHL after stem cell transplant when a patient is at a high risk of relapse or progression.

In terms of NHL, Adcetris is approved to treat, systemic anaplastic large cell lymphoma (ALCL) after failure of other treatment, and primary cutaneous ALCL after failure of other treatment.

The latest FDA approval, for adult patients with previously untreated stage III or IV cHL was based on a clinical trial comparing Adcetris plus chemotherapy — Adriamycin [doxorubicin], vinblastine and dacarbazine (AVD) — to a chemotherapy-only regimen common for cHL treatment — AVD plus bleomycin (ABVD).

After the 1,334 participants received an average of six 28-day cycles of treatment, those treated with Adcetris plus AVD were 23% less likely to experience progression, death, or initiation of new therapy compared with those receiving ABVD. Overall, 18% of patients in the Adcetris plus AVD group experienced disease progression, death, or began new therapy vs. 22% of those on ABVD.

The FDA granted the application to Seattle Genetics, Inc. with its priority review and breakthrough review designations.


11. Zullig LL, Sims KJ, McNeil R, Williams CD, Jackson GL, Provenzale D, Kelley MJ. Cancer Incidence Among Patients of the U.S. Veterans Affairs Health Care System: 2010 Update. Mil Med. 2017 Jul;182(7):e1883-e1891. doi: 10.7205/MILMED-D-16-00371. PubMed PMID: 28810986; PubMed Central PMCID: PMC5650119.

Comments are closed here.


Related Articles

Better Survival for NSCLC Patients Treated by Military Medicine

Does universal healthcare access provided by the MHS translate into improved patient outcomes for non-small cell lung cancer?

Veterans Study Calls for Better Guidance on Lung Cancer Treatment

With increased imaging now detecting lung cancer nodules in sicker patients, a new report suggested that guidelines should be more directive in how to maximize benefit and minimize harm, while taking into account comorbidities and life expectancy.


U.S. Medicine Recommends


More From oncology

Oncology

Better Survival for NSCLC Patients Treated by Military Medicine

Does universal healthcare access provided by the MHS translate into improved patient outcomes for non-small cell lung cancer?

Oncology

Veterans Study Calls for Better Guidance on Lung Cancer Treatment

With increased imaging now detecting lung cancer nodules in sicker patients, a new report suggested that guidelines should be more directive in how to maximize benefit and minimize harm, while taking into account comorbidities and life expectancy.

Oncology

VA/National Cancer Institute Partnership Increases Veteran Access to Trials

Thanks to a new partnership between the National Cancer Institute and the VA, veterans with cancer will now have greater access to potentially lifesaving clinical trials.

Oncology

VA Continues Hepatocellular Screening, but Study Questions the Value

Although a recent study determined that screening veterans with cirrhosis for hepatocellular carcinoma did not reduce the risk of death associated with liver cancer, the VA has no plans to change its screening practices.

Oncology

Testosterone Therapy Not Linked to Aggressive Prostate Cancer in Veterans

Clinicians prescribing supplemental testosterone in men with low levels always have a nagging concern about the possible link between increasing hormone levels and prostate cancer.

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up